AN2 Therapeutics Inc (ANTX)
2.265
0.00 (0.00%)
USD |
NASDAQ |
May 17, 16:00
2.265
0.00 (0.00%)
After-Hours: 20:00
AN2 Therapeutics Cash from Operations (Quarterly): -17.59M for March 31, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -17.59M |
| December 31, 2023 | -17.07M |
| September 30, 2023 | -11.80M |
| June 30, 2023 | -12.82M |
| March 31, 2023 | -11.60M |
| December 31, 2022 | -7.638M |
| September 30, 2022 | -9.487M |
| Date | Value |
|---|---|
| June 30, 2022 | -9.595M |
| March 31, 2022 | -6.742M |
| December 31, 2021 | -8.993M |
| September 30, 2021 | -4.691M |
| June 30, 2021 | -5.257M |
| March 31, 2021 | -1.543M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-17.59M
Minimum
Mar 2024
-1.543M
Maximum
Mar 2021
-9.602M
Average
-9.487M
Median
Sep 2022
Cash from Operations (Quarterly) Benchmarks
| Revance Therapeutics Inc | -65.94M |
| Viking Therapeutics Inc | -6.134M |
| VYNE Therapeutics Inc | -7.982M |
| Aquestive Therapeutics Inc | -10.38M |
| Humacyte Inc | -27.35M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 26.29M |
| Cash from Financing (Quarterly) | 0.349M |
| Free Cash Flow | -59.28M |
| Free Cash Flow Per Share (Quarterly) | -0.5911 |
| Free Cash Flow Yield | -99.77% |